Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
37.00    0.00 (0.00%)
Bid:
35.00
Ask:
39.00
Spread: 4.00 (11.429%)
Market Cap: £17.23m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

AGM Statement

27 May 2015 07:00

RNS Number : 2898O
Cambridge Cognition Holdings PLC
27 May 2015
 

 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

AGM Statement

 

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, will hold its Annual General Meeting today at 10.00am at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ.

 

At the meeting Nick Kerton, Chief Executive Officer, will provide shareholders with the following update:

 

As I outlined in our Preliminary Results statement our financial performance remains in line with market expectations.

 

The contribution from our clinical trials and academic businesses continued to grow in the first quarter. In particular the enlarged US sales team offers an opportunity to enhance both clinical and academic sales in North America and we already have a healthy pipeline of contracts in the safety and tolerability trial space that we expect to convert over the remainder of the year.

 

The return to profitability in our clinical trials and academic businesses enables us to increase investment in our early stage healthcare technology business which bodes well for the future prospects of the Company.

 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Nick Kerton, Chief Executive Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

 

 

 

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Geoff Nash/Simon Hicks

(Corporate Finance)

Malar Velaigam

(Corporate Broking)

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Paul McManus

Mob: 07584 391 303

Lianne Cawthorne

Mob: 07584 391 303

   

 

 

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMPKADPABKDAPB
Date   Source Headline
18th Oct 20247:00 amRNSDirectorate Change
10th Oct 202412:44 pmRNSBlock Listing Return
12th Sep 202412:38 pmRNSDirectorate change
22nd Aug 20247:00 amRNSInterim Results
20th Aug 20247:00 amRNSNotice of Results
12th Aug 202412:15 pmRNSHolding(s) in Company
26th Jul 20247:00 amRNSIssue of Equity and Total Voting Rights
23rd Jul 20247:00 amRNSTrading Update & Board Change
11th Jul 20247:00 amRNSCambridge Cognition secures Innovate UK grant
1st Jul 20244:20 pmRNSHolding(s) in Company
1st Jul 20247:00 amRNSGrant of Options
28th Jun 20241:48 pmRNSResult of AGM & Change of Name of NOMAD & Broker
21st Jun 202411:23 amRNSHolding(s) in Company
20th Jun 20242:15 pmRNSHolding(s) in Company
20th Jun 20242:15 pmRNSHolding(s) in Company
17th Jun 202412:33 pmRNSResults of GM, Open Offer, TVR and PDMR Dealing
6th Jun 20247:00 amRNSNotice of AGM
31st May 20247:00 amRNSCircular Publication and Notice of General Meeting
30th May 20247:00 amRNSResult of Placing and Subscription
29th May 20244:39 pmRNSProposed Placing, Subscription and Open Offer
1st May 20247:00 amRNSPreliminary Results, Trading Update & Board Change
30th Apr 20247:00 amRNSNotice of Results
23rd Apr 20247:00 amRNSCOG spin-out Monument Therapeutics accesses £1.5m
2nd Apr 20244:20 pmRNSTotal Voting Rights and Block Listing Return
21st Mar 20247:00 amRNSFormation of new Scientific Advisory Board
21st Feb 202410:16 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSCambridge Cognition and ActiGraph Partnership
30th Jan 20244:20 pmRNSDirector/PDMR Share Purchases
30th Jan 20247:00 amRNSBoard appointments
30th Jan 20247:00 amRNSTrading Update
18th Dec 20237:00 amRNSGrant of Options
1st Dec 20237:00 amRNSTotal Voting Rights
22nd Nov 20237:00 amRNSChange of Auditor
1st Nov 20237:00 amRNSTotal Voting Rights
24th Oct 20237:00 amRNSAutomated quality assurance for clinical trials
11th Oct 20237:00 amRNSMajor contract win combining solutions
5th Oct 20235:33 pmRNSIssue of Warrants
3rd Oct 20232:43 pmRNSBlock listing Interim Review
28th Sep 20233:35 pmRNSHolding(s) in Company
26th Sep 20237:01 amRNSInterim Results
26th Sep 20237:00 amRNSSecured £3 million Term Loan
4th Sep 20237:00 amRNSNotice of Interim Results
3rd Jul 20237:00 amRNSTotal Voting Rights
28th Jun 20234:26 pmRNSResult of AGM
13th Jun 20237:00 amRNS£2m contract for a pivotal cancer therapy trial
9th Jun 20237:00 amRNSNotice of AGM – Revision to Explanatory Note
6th Jun 20237:00 amRNSPosting of Annual Report & Notice of AGM
31st May 20237:00 amRNSCapital Markets Day
3rd May 20237:00 amRNSResults for the year ended 31 December 2022
26th Apr 20237:00 amRNSInvestor Webinar and Analyst Briefing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.